New combo shot aims to save sight in diabetics

NCT ID NCT05151744

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase II trial tested whether adding vamikibart to the standard treatment ranibizumab improves vision more than ranibizumab alone in people with diabetic macular edema. 187 participants received injections into the eye over 76 weeks. The study is complete, and results will show if the combination is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vamikibart (also called RO7200220) combined with ranibizumab (Lucentis)
What this could lead to: If successful, this combination could offer better vision improvement for people with diabetic macular edema than current standard treatment alone.
What could go wrong: This is a Phase II trial, so results are still early. The combination may not prove more effective or could have additional side effects compared to ranibizumab alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic macular edema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC MACULAR EDEMA

Contacts and locations

Locations

Asan Medical Center

Seoul, 05505, South Korea
Bay Area Retina Associates

Walnut Creek, California, 94598, United States
Buenos Aires Mácula

Ciudad Autonoma Buenos Aires, C1061AAE, Argentina
Caminomed

Tarnowskie Góry, 42-600, Poland
Centro Oftalmológico Dr. Charles S.A.

Capital Federal, C1116, Argentina
Centrum Diagnostyki i Mikrochirurgii Oka LENS

Olsztyn, 10-424, Poland
Centrum Medyczne UNO-MED

Krakow, 31-070, Poland
Clinica Universitaria de Navarra

Pamplona, Navarre, 31008, Spain
Clinica Universitaria de Navarra

Madrid, 28027, Spain
Cumberland Valley Retina Consultants

Hagerstown, Maryland, 21740, United States
Deep Blue Retina PLLC

Southaven, Mississippi, 38671, United States
Emanuelli Research and Development Center LLC

Arecibo, 00613, Puerto Rico
Florida Eye Associates

Melbourne, Florida, 30394-7344, United States
Gloucestershire Hospitals NHS Foundation Trust

Gloucestershire, GL1 3NN, United Kingdom
Grupo Laser Vision

Rosario, S2000DLA, Argentina
Hadassah MC

Jerusalem, 9112001, Israel
Institut De L'Oeil Des Laurentides

Boisbriand, Quebec, J7H 0E8, Canada
Kaplan Medical Center

Rehovot, 7660101, Israel
Kim's Eye Hospital

Seoul, 07301, South Korea
Kings College Hospital NHS Foundation Trust

London, SE5 9RS, United Kingdom
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Torrance, California, 90502, United States
Niepubliczny Zak?ad Opieki Zdrowotnej PRYZMAT-OKULISTYKA

Gliwice, 44-100, Poland
Oftalmos

Capital Federal, C1120AAN, Argentina
Organizacion Medica de Investigacion

Buenos Aires, C1015ABO, Argentina
Pusan National University Hospital

Busan, 49241, South Korea
Rabin MC

Petah Tikva, 4941492, Israel
Rambam Medical Center

Haifa, 3109601, Israel
Retina Consultants of Texas

Bellaire, Texas, 77401, United States
Retina Institute of Ottawa

Ottawa, Ontario, K2B 7E9, Canada
Retina Vitreous Associates of Florida

Tampa, Florida, 33617, United States
Royal Surrey County Hospital

Guildford, GU2 7XX, United Kingdom
Samsung Medical Center

Seoul, 06351, South Korea
Tel Aviv Sourasky MC

Tel Aviv, 6423906, Israel
Texas Retina Associates

Arlington, Texas, 76012, United States
Toronto Retina Institute

Toronto, Ontario, M3C 0G9, Canada
Verum Research LLC

Eugene, Oregon, 97401, United States
Win Retina

Arcadia, California, 91006, United States
Yeungnam University Medical Center

Daegu, 42415, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.